Patents by Inventor Keith Hildebrand
Keith Hildebrand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100030196Abstract: A system includes (i) a medium having a solid support to which an antibody directed to target molecule is bound, (ii) a reservoir for containing the medium, (iii) a first catheter, and (iv) a second catheter. The first catheter has a proximal end portion, an opening for removal of cerebrospinal fluid from a subject, and a lumen extending from the proximal end portion to the opening. The first catheter is operably couplable to the reservoir such that fluid is capable of flowing from the lumen to the reservoir. The second catheter has a proximal end portion, a delivery region for returning cerebrospinal fluid to the subject, and a lumen extending from the proximal end portion to the delivery region. The second catheter is operably couplable to the reservoir such that fluid is capable of flowing from the reservoir to the lumen.Type: ApplicationFiled: July 29, 2009Publication date: February 4, 2010Applicant: MEDTRONIC, INC.Inventors: Keith Hildebrand, Lisa Lynn Shafer, Deepak Ramesh Thakker
-
Publication number: 20070253995Abstract: The disclosure describes a method and system for delivering a drug to the Onuf's nucleus of a patient for the treatment or prevention of stress urinary incontinence. The system includes drug delivery devices that deliver one or more drugs to a site located adjacent to, around or within the Onuf's nucleus stress incontinence alleviation. A depot configured to release a therapeutically effective amount of a stress incontinence-reducing drug is one drug delivery device disclosed. Other drug delivery devices include implantable infusion pumps.Type: ApplicationFiled: April 28, 2006Publication date: November 1, 2007Applicant: Medtronic, Inc.Inventor: Keith Hildebrand
-
Publication number: 20070253994Abstract: The disclosure describes methods and systems for alleviating chronic pelvic pain in a subject by intraspinally a therapeutically effective amount of a chronic pelvic pain-alleviating drug. The system includes drug delivery devices and systems for the controlled administration of drugs for alleviation of pelvic pain. The system may deliver drug therapy for pelvic pain in men or women.Type: ApplicationFiled: April 28, 2006Publication date: November 1, 2007Applicant: Medtronic, Inc.Inventor: Keith Hildebrand
-
Publication number: 20070251530Abstract: Pharmaceutical depots and methods for screening patients to identify good candidates for implantable infusion device therapy are described. A pharmaceutical depot is placed in a target region of a patient of a pharmaceutical depot configured to release a therapeutic agent in a manner similar to what would be achieved by an implantable infusion system, e.g. small amounts over a period of time. Following depot placement, the patient can be evaluated to determine whether at least one symptom of a disease or general quality of life has improved. If an improvement results, the patient is identified as a good candidate for receiving an implantable infusion device to deliver the therapeutic agent to the target region to treat the disease.Type: ApplicationFiled: April 28, 2006Publication date: November 1, 2007Applicant: Medtronic, Inc.Inventor: Keith Hildebrand
-
Publication number: 20060293389Abstract: Injectable compositions containing gabapentin and processes for preparing sterile injectable compositions containing gabapentin are discussed. The process includes subjecting the compositions to heat. Heating results in increased production of gabapentin lactam, which has previously been shown to be toxic. Surprisingly, heated injectable compositions containing gabapentin are found to be non-toxic when administered intrathecally. Thus, heating for the purposes of sterilization or to assure sterility provides a viable option in the production of injectable compositions containing gabapentin.Type: ApplicationFiled: July 21, 2006Publication date: December 28, 2006Applicant: Medtronic, Inc.Inventors: Keith Hildebrand, Linda Page, Deanna Lane, Dennis Elsberry, David Clarahan, Jayantha Ratnayake
-
Publication number: 20060160900Abstract: Methods for treating pain by administering gabapentin to cerebrospinal fluid of a patient are discussed. Compositions, particularly injectable compositions, containing gabapentin are also discussed. In addition, systems including an implantable pump having a reservoir for housing a composition, a catheter having a proximal portion coupled to the pump and having a distal portion adapted for administrating a composition to a cerebrospinal fluid of a patient, and a composition containing gabapentin, which composition is housed in the reservoir of the pump, is also discussed.Type: ApplicationFiled: March 29, 2006Publication date: July 20, 2006Applicant: Medtronic, Inc.Inventors: Keith Hildebrand, Linda Page, Deanna Lane, Dennis Elsberry, David Clarahan, Jayantha Ratnayake
-
Publication number: 20060160899Abstract: Methods for treating epilepsy by administering gabapentin to cerebrospinal fluid and brain tissue of a patient are discussed. Compositions, particularly injectable compositions, containing gabapentin are also discussed. In addition, systems including an implantable device having a pump coupled to a reservoir for housing a composition, a catheter having a proximal end coupled to the pump and having a distal end adapted for administrating a composition to a cerebrospinal fluid of a patient, and a composition containing gabapentin, which composition is housed in the reservoir of the pump, are also discussed.Type: ApplicationFiled: March 29, 2006Publication date: July 20, 2006Applicant: Medtronic, Inc.Inventors: Keith Hildebrand, Linda Page, Deanna Lane, Dennis Elsberry, David Clarahan, Jayantha Ratnayake
-
Publication number: 20060111690Abstract: A method and system for treating depressive and anxiety disorders is disclosed. The method and system of the present invention comprises operating a programmable pump for the delivery of at least one therapeutic substance into the cerebrospinal fluid of a patient for the treatment of depressive or anxiety disorders. In an embodiment, a sensor implanted in a patient may be used in combination with the programmable pump and catheter.Type: ApplicationFiled: September 20, 2005Publication date: May 25, 2006Applicant: Medtronic, Inc.Inventor: Keith Hildebrand
-
Publication number: 20050177135Abstract: A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms and otherwise treat heart failure (HF) and pathologies associated with HF. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with HF (or pathologies associated with HF) and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist, e.g.Type: ApplicationFiled: February 6, 2004Publication date: August 11, 2005Inventors: Keith Hildebrand, Michael Ujhelyi, Xiaohong Zhou, Daniel Sigg, Linda Page
-
Publication number: 20050177097Abstract: A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g.Type: ApplicationFiled: July 30, 2004Publication date: August 11, 2005Inventors: Keith Hildebrand, Michael Ujhelyi, Xiaohong Zhou, Daniel Sigg, Linda Page
-
Publication number: 20050090548Abstract: Methods for treating epilepsy by administering gabapentin to cerebrospinal fluid and brain tissue of a patient are discussed. Compositions, particularly injectable compositions, containing gabapentin are also discussed. In addition, systems including an implantable device having a pump coupled to a reservoir for housing a composition, a catheter having a proximal end coupled to the pump and having a distal end adapted for administrating a composition to a cerebrospinal fluid of a patient, and a composition containing gabapentin, which composition is housed in the reservoir of the pump, are also discussed.Type: ApplicationFiled: March 24, 2004Publication date: April 28, 2005Applicant: Medtronic, Inc.Inventors: Keith Hildebrand, Linda Page, Deanna Lane, Dennis Elsberry, David Clarahan, Jayantha Ratnayake
-
Publication number: 20050090549Abstract: Methods for treating pain by administering gabapentin to cerebrospinal fluid of a patient are discussed. Compositions, particularly injectable compositions, containing gabapentin are also discussed. In addition, systems including an implantable pump having a reservoir for housing a composition, a catheter having a proximal portion coupled to the pump and having a distal portion adapted for administrating a composition to a cerebrospinal fluid of a patient, and a composition containing gabapentin, which composition is housed in the reservoir of the pump, is also discussed.Type: ApplicationFiled: March 24, 2004Publication date: April 28, 2005Applicant: Medtronic, Inc.Inventors: Keith Hildebrand, Linda Page, Deanna Lane, Dennis Elsberry, David Clarahan, Jayantha Ratnayake
-
Publication number: 20050048641Abstract: Methods and apparatuses for delivering RNA polynucleotides to a patient in need thereof are described. Programmable infusion pump systems that include a reservoir housing the RNA polynucleotide are implanted in the patient. The RNA polynucleotide is delivered to a target location in the patient via a catheter in communication with the reservoir. The pump system may include one or more sensors that may control rate or timing of delivery of the RNA polynucloetide based on a detected event. The pump system allows for controlled delivery of RNA polynucleotides for the treatment of diseases, disorders, or conditions.Type: ApplicationFiled: October 12, 2004Publication date: March 3, 2005Applicant: Medtronic, Inc.Inventors: Keith Hildebrand, William Kaemmerer
-
Publication number: 20050004221Abstract: Injectable compositions containing gabapentin and having reduced tonicity are discussed. One such injectable gabapentin composition contains greater than about 30 mg/ml gabapentin and has a tonicity of less than about 900 mOsm. Another such injecable gabapentin composition contains less that 0.9% sodium chloride. A process for preparing injectable gabapentin compositions are also discussed. The process includes determining and optionally adjusting tonicity of a gabapentin composition.Type: ApplicationFiled: March 24, 2004Publication date: January 6, 2005Applicant: Medtronic, Inc.Inventors: Keith Hildebrand, Linda Page, Deanna Lane, Dennis Elsberry, David Clarahan, Jayantha Ratnayake
-
Publication number: 20050004219Abstract: A system including a reservoir, a pump coupled to the reservoir, a catheter coupled to the pump and adapted for delivering a therapeutic agent to a cerebrospinal fluid of a patient; and an injectable gabapentin composition housed in the reservoir and deliverable through the catheter, is discussed. The injectable gabapentin composition may have reduced tonicity. One such injectable gabapentin composition contains greater than about 30 mg/ml gabapentin and has a tonicity of less than about 900 mOsm. Another such injecable gabapentin composition contains less that 0.9% sodium chloride.Type: ApplicationFiled: March 24, 2004Publication date: January 6, 2005Applicant: Medtronic, Inc.Inventors: Keith Hildebrand, Linda Page, Deanna Lane, Dennis Elsberry, David Clarahan, Harris Ratnayake
-
Publication number: 20050004220Abstract: Injectable compositions containing gabapentin and processes for preparing sterile injectable compositions containing gabapentin are discussed. The process includes subjecting the compositions to heat. Heating results in increased production of gabapentin lactam, which has previously been shown to be toxic. Surprisingly, heated injectable compositions containing gabapentin are found to be non-toxic when administered intrathecally. Thus, heating for the purposes of sterilization or to assure sterility provides a viable option in the production of injectable compositions containing gabapentin.Type: ApplicationFiled: March 24, 2004Publication date: January 6, 2005Applicant: Medtronic, Inc.Inventors: Keith Hildebrand, Linda Page, Deanna Lane, Dennis Elsberry, David Clarahan, Jayantha Ratnayake